Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $95
PTC Therapeutics, Inc.
PTC Therapeutics, Inc. PTCT | 0.00 |
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:
PTCT) with a Overweight and raises the price target from $86 to $95.